|Bid||0.00 x 1000|
|Ask||0.00 x 3200|
|Day's Range||4.70 - 6.15|
|52 Week Range||1.83 - 32.93|
|Beta (5Y Monthly)||1.81|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 07, 2022 - Nov 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
Subscribe to Yahoo Finance Plus to view Fair Value for NVTA
Shares of the genetic testing company have more than doubled in less than a week. It likely isn't durable.
Even as Invitae increases its margins and reduces cash burn, eager traders still might have gotten ahead of themselves.
Shares of Invitae (NYSE: NVTA) recently shot up like a rocket in response to a second-quarter earnings call that was a lot more positive than expected. Bringing comprehensive genetic information into mainstream medicine could make Invitae a top performer in the years ahead. Let's look a little closer at the company's performance this year to see if it's a smart stock to buy now and hold for the long run.